Background: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated patients. ) every 14 days. Multidisciplinary decisions to resect LM were taken after every three courses. The rate of macroscopic complete resections (R0 + R1) of LM, progression-free survival (PFS) and overall survival (OS) were computed according to intent to treat.
introduction Liver metastases (LM) affect nearly half of the 1.4 million patients who present with colorectal cancer worldwide each year [1] , and represent the main cause of colorectal cancer mortality [2] . Aggressive liver-specific medico-surgical strategies however can shrink LM and enable macroscopically complete liver resection (R0-R1) resulting in consistent long-term survival [3] [4] [5] . However, hepatectomies with curative intent could typically be performed in only 15% of all patients with initially unresectable LM, following downsizing through systemic conventional or chronomodulated chemotherapy [5] . Thus, there is a need to further reinforce the targeting of current treatment strategies toward the liver, possibly through hepatic artery infusions of chemotherapy in order to attempt improve long-term survival in colorectal cancer patients [6] [7] [8] [9] [10] .
The OPTILIV trial readily integrates hepatic artery infusion (HAI) chemotherapy into a curative intent medico-surgical strategy, with (R0-R1) hepatectomy being the primary end point, in patients who have received one to three prior systemic chemotherapy protocols. To maximize efficacy, OPTILIV combines irinotecan, 5-fluorouracil (5-FU) and oxaliplatin being given into the hepatic artery and cetuximab intravenously. The systemic administration of such triplet cytostatic combination therapy has been shown to be highly effective in downsizing LM and enabling surgical resection, as first-line treatment for metastatic disease [11] [12] [13] . The addition of cetuximab to systemic doublet or triplet chemotherapy could further enhance tumor response and resection rates and prolong survival, although this issue remains controversial [14] [15] [16] [17] [18] [19] . Chronomodulated HAI of irinotecan-5-FU-oxaliplatin further enabled macroscopically complete (R0-R1) liver resection in 14% of 29 patients with unresectable LM following failure of a median of four prior systemic chemotherapy protocols [20] . Despite this very advanced setting, median OS was 18 months [20] . We reasoned that the combination of systemic cetuximab and triplet HAI could both represent the most effective regimen for LM downsizing, and enable adequate systemic treatment for controlling or preventing extrahepatic dissemination in previously treated patients with wt KRAS colorectal cancer. This hypothesis was tested in the prospective multicenter phase II trial OPTILIV. 
patients
Patients had histological or cytological proof of colorectal adenocarcinoma, with wild-type exon 2 KRAS. LM resection with curative intent had to be deferred at medico-surgical multidisciplinary review meetings involving an experienced hepato-biliary surgeon. Trial inclusion required at least one of the following criteria: (i) less than 30% residual liver expected after resection, (ii) malignant disease in contact with either three hepatic veins, both portal veins or the retrohepatic vena cava, (iii) documented progressive disease (PD) on imaging or doubling of serum levels of carcinoembryonic antigen (CEA) or CA19.9 over the prior 90 days or less [21] . At least one LM had to be measurable according to RECIST. Up to three extrahepatic resectable lesions of ≤10 mm were allowed. Eligible patients had received one to three prior systemic chemotherapy protocols. Other main inclusion criteria were World Health Organization (WHO) performance status (PS) of 0 or 1, absolute neutrophil count ≥10 9 /l, platelet count ≥75×10 Figure S1 , available at Annals of Oncology online). The radiological patency of the arterial catheter and the isolated perfusion of the whole liver were checked with contrast angiography before each course. The intravenous delivery of the same cetuximab-triplet combination protocol was planned in case of HAI interruption for causes other than PD or severe toxicity. Cetuximab-triplet was recommended after liver surgery for up to eight postoperative courses.
toxicity and response assessments
Blood cell counts, renal and liver serum biochemistry and plasma CEA and CA19.9 were determined before each course. PS and adverse events were graded according to WHO and NCI-CTCAE v3.0, respectively, before each course. A thoraco-abdomino-pelvic computed tomography (CT) scan was performed within at least 1 month of inclusion, and after every third treatment course subsequently. The sum of the largest diameters of the target lesions was computed on the inclusion CT scan and used as baseline for the quantification of centrally reviewed tumor downsizing and response categorization according to RECIST. Maximum tumor response, as achieved while on triplet HAI or within the month following its cessation, was classified as complete, partial, stable or PD.
liver surgery
Decision for indication to undertake liver surgery was made at systematic multidisciplinary evaluations after every three courses. Partial hepatectomies were undertaken whenever a complete macroscopic resection of all the detected LM was foreseen, occasionally involving intraoperative radiofrequency ablation of ill-located lesions. In such cases, hepatectomy was rated as R0-R1. Further histopathology analysis was performed in the resected liver specimen for counting LM, estimating necrosis and fibrosis, assessing resection margins and any toxic lesion in the nonmalignant liver.
statistical consideration
OPTILIV aimed to increase the rate of macroscopic complete resection (R0 + R1) from a historical control rate of 15% (P 0 = 0.15) on currently available systemic neoadjuvant chemotherapy [5] [6] [7] [8] up to 30% (P 1 = 0.30), with α = 5% and β = 20%, according to the exact single-stage phase II design method [22] . This required the inclusion of 48 assessable patients for the primary outcome. A 30% rate of nonassessable patients was expected for
original articles Annals of Oncology technical reasons such as arterial complications, which could lead to HAI withdrawal within the first 2 months. As a result, the inclusion of 64 patients was planned (supplementary Text S1, available at Annals of Oncology online). All analyses were carried out with intent-to-treat using SPSS® v18.0 software (Chicago, IL). A P value <0.05 was considered statistically significant using bilateral tests.
results

patient characteristics
Sixty-four patients were registered from May 2008 to March 2012. Initial nonindication to LM resection was specified for 58 patients (90.6%), and was based on an estimated residual liver of <30% after curative intent surgery (56.3% of the patients), tight disease contact with liver main vessels (55.2%) and/or PD (73.4%). The majority of patients had bilobar LM, high number of LM and segments involved and large LM ( Table 1) . Extrahepatic disease was documented for 40.6% of the patients. All the patients had received prior chemotherapy (supplementary Table S1 , available at Annals of Oncology online). The majority of patients had received two or more chemotherapy protocols for metastatic disease. HAI catheter placement was through interventional radiology for 49 patients (77%) or surgery for 15 patients (23%) for whom LM resection was deferred at laparotomy. The 61 treated patients received a total of 363 protocol courses, resulting in a median number of six courses per patient (1-20) for a median protocol treatment duration of 2.8 months (1st to 3rd quartiles, 1.5-4.1) (Figure 1 ).
surgery of liver metastases (R0-R1), disease-free survival and patterns of relapse . Multivariate logistic regression revealed that an age below the median of 58 years (P = 0.006), a single prior chemotherapy protocol (P = 0.006) and 10 or fewer LM (P = 0.001) were the main independent predictive factors for achieving R0-R1 resection (supplementary Table S3 , available at Annals of Oncology online). The median disease-free Figure 3A and B). The successful conversion to R0-R1 resection resulted in a median PFS of 15.7 months (12.7-18.7), while median PFS was 8.6 months (6.4-10.9) in the nonresected patients (P < 0.001) ( Figure 3C ). The median OS of the 19 LM resected patients reached 35.2 months (32.6-37.8), when compared with 18.7 months (12.1-25.3) for the nonresected ones (P < 0.001) ( Figure 3D ). These results were supported by landmark analysis, involving 11 patients with R0-R1 resection before the prespecified landmark of 6 months. The median OS of these patients was 35.2 months (23.6-48.8), when compared with 21.9 (14.0-9.8) for the 53 other patients including 8 who had liver surgery afterwards (P = 0.036). Multivariate Cox model analysis identified R0-R1 resection, initial liver replacement by tumor and sex as independent prognostic factors for both PFS and OS (with best outcomes for female patients), while the number of prior chemotherapy lines was prognostic for OS only (supplementary Table S3 , available at Annals of Oncology online).
impact of medico-surgical strategy as second-line treatment
The medico-surgical strategy conducted here achieved secondary R0-R1 resection in 13 of the 28 patients enrolled in OPTILIV for second-line treatment (46.4%), when compared with 6 of the 36 patients recruited for third to fourth line (16.7%) (P = 0.014). Respective median PFS were 10.1 months (7.8-12.3) and 8.5 months (5.8-11.2) (P = 0.088). OS was twice as large for the patients completing the OPTILIV medico-surgical strategy as second rather than third to fourth treatment protocol, despite similar other characteristics (data not shown). Thus, the respective median survival times were 31.8 months (26.0-37.6) when compared with 15.7 months (10.1-21.2) (P = 0.001) ( Figure 3E and F) .
discussion
This is the first prospective international trial, whose primary end point is the conversion of initially uncontrolled and/or unresectable LM from colorectal cancer to resection, employing an aggressive liver-specific medico-surgical strategy. The main end point was met, achieving a complete macroscopic resection rate of LM in nearly 30% of all included patients with initially unresectable LM, as defined by the high number of LM, the bilaterality of the metastases, the high number of segments involved, the large size of the largest lesion, the ill-location of the metastases and 'oncological' non indication for surgery based on disease progression [5, 21] . The incidence and type of adverse events seen were in line with those encountered with systemic combinations of first-line cetuximab and triplet chemotherapy [18, 23] . The only specific adverse event was abdominal pain, an effect that was likely related to the vascular toxicity of the drugs, particularly oxaliplatin [6, 8] . However, pain was well controlled with analgesics. The major complications of the protocol treatments were hepatic artery thrombosis or arteritis, which led to the interruption of HAI delivery for nearly half of patients after a median number of six courses. This rate was 34% in our previous monocentric study using the same triplet HAI with a 3-weekly schedule, no cetuximab and no contrast liver angiography before each course [20] . The shorter interval for allowing recovery between courses, the addition of cetuximab [24] and the thorough assessment of liver artery permeability, could account for this apparent increase [25] . A prophylaxis scheme involving the HAI of dexamethasone (8 mg) and heparin 3000 IU both before and after each HAI course, was gradually implemented based on similar work using continuous HAI of floxuridine (FUDR) [7] . Nevertheless, the catheter-related events had no clinical significance as collateral arterial vascularization developed quickly. No biliary toxicity was observed, in contrast to what is known for the HAI of FUDR [6] .
The OPTILIV strategy met highest expectations in this advanced disease population involving patients receiving treatment as median third-line chemotherapy, and overcoming clinical resistance to the same agents. Indeed, the 40.6% rate of objective responses and the 9.3 and 25.5 months found for median PFS and OS, respectivel,y compare very favorably with the most effective recent systemic second or third-line chemotherapy protocols [25] [26] [27] [28] .
OPTILIV further shifted the concept of using single-agent FUDR or oxaliplatin HAI as an adjunct to systemic chemotherapy [6] [7] [8] 29] toward HAI of combination chemotherapy, and its modulation with systemic targeted agents in order to help convert LM to resection. This intensive liver-specific medico-surgical treatment strategy offered potential cures and long-term survival for patients with metastatic colorectal cancer in an international multicenter setting, despite the patients had prior chemotherapy and often prior liver surgery, prior progression on systemic chemotherapy and frequently concurrent extrahepatic disease. Patients on OPTILIV as second-line therapy clearly received the greatest benefit from this aggressive medico-surgical strategy. Nearly half of them had R0-R1 resection, and more than half of resected patients were alive at 4 years. However, the sample size of the patient subgroups is limited, so confirmatory studies are needed.
In conclusion, we claim that the OPTILIV strategic protocol offers patients with metastatic colorectal cancer a better chance of prolonged survival and possibly cure when compared with current standard practice. Indeed, the most recent first-line systemic chemotherapy protocols for colorectal cancer LM achieved a 5-year survival rate of 5%-15% at best [30, 31] . Application of the OPTILIV strategy could bring this figure up to 40%, a hypothesis that deserves randomized comparative trial assessment. 
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